RT Book, Section
A1 Desai Gini Fleming, Apurva A.
A2 Hall, Jesse B.
A2 Schmidt, Gregory A.
A2 Wood, Lawrence D.H.
SR Print(0)
ID 2294312
T1 Chapter 74. Toxicities of Chemotherapy
T2 Principles of Critical Care, 3e
YR 2005
FD 2005
PB The McGraw-Hill Companies
PP New York, NY
SN 9780071416405
LK accessanesthesiology.mhmedical.com/content.aspx?aid=2294312
RD 2023/09/28
AB Drug  toxicity  is  most  often  a  diagnosis  of  exclusion.Dose,  schedule,  and  drug  combinations  are  key  parameters  used  to  determine  the  likelihood  of  drug  toxicity.Not  all  toxicities  are  known,  and  drug  regimens  are  modified  constantly.Therapy  is  supportive  for  most  chemotherapy-related  toxicities.Pelvic  and  spinal  irradiation  potentiates  the  myelosuppressive  effects  of  chemotherapeutic  agents.Bleomycin  and  gemcitabine  are  among  the  causes  of  drug-related  interstitial  lung  disease.Most  cardiac  events  in  cancer  patients  are  related  to  pre-existing  heart  disease  or  direct  invasion  of  the  heart  by  cancer;  nonetheless,  drug  toxicity  must  be  considered,  particularly  when  high-dose  cyclophosphamide  and  anthracyclines  have  been  administered.In  high-dose  regimens,  cytosine  arabinoside,  ifosfamide,  and  methotrexate  may  produce  dramatic  central  nervous  system  syndromes.Renal  injury  is  often  dose  limiting  for  cisplatin.Cytokines  such  as  interleukin-2  have  a  wide  range  of  toxicities  involving  virtually  all  organ  systems.Many  commonly  used  chemotherapeutic  agents  and  several  recently  introduced  targeted  anticancer  agents  are  associated  with  hypersensitivity  reactions.Thrombotic  microangiopathy  is  associated  with  various  chemotherapeutic  agents,  particularly  gemcitabine  and  mitomycin-C.